Combinational products: A regulatory review

J. Vijaya Dwaraka, S. G. Vasantharaju, Latif Jamadar, Syed Sajjad Hussen, D. Sreedhar, N. Udupa

Research output: Contribution to journalReview article

Abstract

A regulation with respect to combination products and FDA over view. Advances in drug, biologic and medical device development relate to both single entities and combination of each type of medicinal product. Regulatory overview of combination products is complicated by the fact that although drugs are regulated primarily under section 505 of Food, drugs and cosmetic act and reviewed by CDER, CBER, and CDRH. Combination products increasingly include state-of-art, innovative technologies with great potential to advance patient care. Combining different regulated product types, however, triggers a panoply of issues with which the Food and Drug Administration, pharmaceutical, biologic and medical device manufacturers, and other stake holders have struggled through the years. Since 1991, FDA has worked toward resolving a number of these issues, and has made some inroads in assignment of jurisdiction for combination products. We are encouraged by FDA's preliminary efforts, and look forward to further improvement in the regulatory process for combination products.

Original languageEnglish
Pages (from-to)52-60
Number of pages9
JournalInternational Journal of Pharmaceutical Sciences Review and Research
Volume5
Issue number1
Publication statusPublished - 11-2010

Fingerprint

Pharmaceutical Preparations
Drug Legislation
Equipment and Supplies
United States Food and Drug Administration
Patient Care
Technology

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

@article{67bafb93cd694cd4a3a7060e8ed66bfb,
title = "Combinational products: A regulatory review",
abstract = "A regulation with respect to combination products and FDA over view. Advances in drug, biologic and medical device development relate to both single entities and combination of each type of medicinal product. Regulatory overview of combination products is complicated by the fact that although drugs are regulated primarily under section 505 of Food, drugs and cosmetic act and reviewed by CDER, CBER, and CDRH. Combination products increasingly include state-of-art, innovative technologies with great potential to advance patient care. Combining different regulated product types, however, triggers a panoply of issues with which the Food and Drug Administration, pharmaceutical, biologic and medical device manufacturers, and other stake holders have struggled through the years. Since 1991, FDA has worked toward resolving a number of these issues, and has made some inroads in assignment of jurisdiction for combination products. We are encouraged by FDA's preliminary efforts, and look forward to further improvement in the regulatory process for combination products.",
author = "{Vijaya Dwaraka}, J. and Vasantharaju, {S. G.} and Latif Jamadar and Hussen, {Syed Sajjad} and D. Sreedhar and N. Udupa",
note = "cited By 0",
year = "2010",
month = "11",
language = "English",
volume = "5",
pages = "52--60",
journal = "International Journal of Pharmaceutical Sciences Review and Research",
issn = "0976-044X",
publisher = "Global Research Online",
number = "1",

}

Combinational products: A regulatory review. / Vijaya Dwaraka, J.; Vasantharaju, S. G.; Jamadar, Latif; Hussen, Syed Sajjad; Sreedhar, D.; Udupa, N.

In: International Journal of Pharmaceutical Sciences Review and Research, Vol. 5, No. 1, 11.2010, p. 52-60.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Combinational products: A regulatory review

AU - Vijaya Dwaraka, J.

AU - Vasantharaju, S. G.

AU - Jamadar, Latif

AU - Hussen, Syed Sajjad

AU - Sreedhar, D.

AU - Udupa, N.

N1 - cited By 0

PY - 2010/11

Y1 - 2010/11

N2 - A regulation with respect to combination products and FDA over view. Advances in drug, biologic and medical device development relate to both single entities and combination of each type of medicinal product. Regulatory overview of combination products is complicated by the fact that although drugs are regulated primarily under section 505 of Food, drugs and cosmetic act and reviewed by CDER, CBER, and CDRH. Combination products increasingly include state-of-art, innovative technologies with great potential to advance patient care. Combining different regulated product types, however, triggers a panoply of issues with which the Food and Drug Administration, pharmaceutical, biologic and medical device manufacturers, and other stake holders have struggled through the years. Since 1991, FDA has worked toward resolving a number of these issues, and has made some inroads in assignment of jurisdiction for combination products. We are encouraged by FDA's preliminary efforts, and look forward to further improvement in the regulatory process for combination products.

AB - A regulation with respect to combination products and FDA over view. Advances in drug, biologic and medical device development relate to both single entities and combination of each type of medicinal product. Regulatory overview of combination products is complicated by the fact that although drugs are regulated primarily under section 505 of Food, drugs and cosmetic act and reviewed by CDER, CBER, and CDRH. Combination products increasingly include state-of-art, innovative technologies with great potential to advance patient care. Combining different regulated product types, however, triggers a panoply of issues with which the Food and Drug Administration, pharmaceutical, biologic and medical device manufacturers, and other stake holders have struggled through the years. Since 1991, FDA has worked toward resolving a number of these issues, and has made some inroads in assignment of jurisdiction for combination products. We are encouraged by FDA's preliminary efforts, and look forward to further improvement in the regulatory process for combination products.

UR - http://www.scopus.com/inward/record.url?scp=79952029279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952029279&partnerID=8YFLogxK

M3 - Review article

VL - 5

SP - 52

EP - 60

JO - International Journal of Pharmaceutical Sciences Review and Research

JF - International Journal of Pharmaceutical Sciences Review and Research

SN - 0976-044X

IS - 1

ER -